8 research outputs found
Lernstrategien und Lernerfolg im Studium : zur Validierung des LIST bei berufstätigen Studierenden
Das von Wild und Schiefele (1994) vorgestellte Inventar zur Erfassung von Lernstrategien im Studium (LIST) wird an einer Stichprobe von N = 577 berufstätigen Studierenden vier unterschiedlicher Hochschulen untersucht. Die von Wild und Schiefele angenommene Struktur der kognitiven, ressourcenbezogenen und metakognitiven Lernstrategien wird hier erstmals faktorenanalytisch überprüft. Darüber hinaus wird erstmals die dreifaktorielle Struktur der metakognitiven Lernstrategien mit dem LISTInventar nachgewiesen. Schließlich sind im Sinne einer Außenvalidierung des LIST Zusammenhänge zwischen Lernstrategien und Lernerfolg der Studierenden nachweisbar
Strategien selbstorganisierten Lernens bei berufstätigen Studierenden : ausgewählte Ergebnisse einer empirischen Untersuchung
Selbstgesteuertes Lernen im Fernstudium : Ergebnisse einer Studie an den AKAD Privathochschulen
Eine empirische Untersuchung zum berufsbegleitenden Studium im Bankenbereich : Innovationsfähige Mitarbeiter durch Weiterbildung
The Mu-Opioid Receptor Variant N190K is Unresponsive to Peptide Agonists Yet Can be Rescued by Small Molecule Drugs MOL #64188 2 Running Title: Small molecules rescue function of an inactive MOR variant
MOL #64188 3 Abstract The mu-opioid receptor (MOR) plays an important role in modulating analgesia, feeding behavior and a range of autonomic functions. In the current study, we investigated the degree to which thirteen naturally-occurring missense mutations affect the pharmacological properties of the human MOR. Following expression of each receptor in HEK293 cells, signaling (Gα i/omediated) induced by peptide agonists was assessed utilizing luciferase reporter gene assays. Multiple mutants (S66F, S147C, R260H, R265C, R265H and S268P) show a significant reduction in agonist potency. At the N190K variant, agonist-mediated signaling was essentially absent. ELISA, microscopic analysis and radioligand binding assays revealed that this mutant shows markedly reduced cell surface expression, whereas all other receptor variants were expressed at normal levels. Surface expression of the N190K variant could be increased by incubation with the alkaloid agonist buprenorphine, or with either of the structurally related MOR antagonists, naltrexone or naloxone. Surprisingly, both putative antagonists, despite being inactive at the wild type MOR, triggered a concentration-dependent increase in N190K receptor mediated signaling. In contrast, peptidic ligands failed to promote expression or rescue function of the N190K mutant. Subsequent analysis of the N190K variant in an ethnically diverse cohort identified this isoform in a subgroup of African Americans. Taken together, our studies reveal that the N190K mutation leads to severe functional alterations and, in parallel, changes the response to established MOR ligands. The extent to which this mutation results in physiological abnormalities or affects drug sensitivity in selected populations (e.g. those with chronic pain or addiction) remains to be investigated
The μ-Opioid Receptor Variant N190K Is Unresponsive to Peptide Agonists yet Can be Rescued by Small-Molecule DrugsS⃞
The μ-opioid receptor (MOR) plays an important role in modulating
analgesia, feeding behavior, and a range of autonomic functions. In the current
study, we investigated the degree to which 13 naturally occurring missense mutations
affect the pharmacological properties of the human MOR. After expression of each
receptor in human embryonic kidney 293 cells, signaling
(Gαi/o-mediated) induced by peptide agonists was assessed
using luciferase reporter gene assays. Multiple mutants (S66F, S147C, R260H, R265C,
R265H, and S268P) show a significant reduction in agonist potency. At the N190K
variant, agonist-mediated signaling was essentially absent. Enzyme-linked
immunosorbent assay, microscopic analysis, and radioligand binding assays revealed
that this mutant shows markedly reduced cell-surface expression, whereas all other
receptor variants were expressed at normal levels. Surface expression of the N190K
variant could be increased by incubation with the alkaloid agonist buprenorphine or
with either naltrexone or naloxone, structurally related MOR antagonists. We were
surprised to find that both putative antagonists, despite being inactive at the
wild-type MOR, triggered a concentration-dependent increase in N190K
receptor-mediated signaling. In contrast, peptidic ligands failed to promote
expression or rescue function of the N190K mutant. Subsequent analysis of the N190K
variant in an ethnically diverse cohort identified this isoform in a subgroup of
African Americans. Taken together, our studies reveal that the N190K mutation leads
to severe functional alterations and, in parallel, changes the response to
established MOR ligands. The extent to which this mutation results in physiological
abnormalities or affects drug sensitivity in selected populations (e.g., those with
chronic pain or addiction) remains to be investigated
Neuropeptide substance P and the immune response
Substance P is a peptide mainly secreted by neurons and is involved in many biological processes, including nociception and inflammation. Animal models have provided insights into the biology of this peptide and offered compelling evidence for the importance of substance P in cell-to-cell communication by either paracrine or endocrine signaling. Substance P mediates interactions between neurons and immune cells, with nerve-derived substance P modulating immune cell proliferation rates and cytokine production. Intriguingly, some immune cells have also been found to secrete substance P, which hints at an integral role of substance P in the immune response. These communications play important functional roles in immunity including mobilization, proliferation and modulation of activity of immune cells. This Review summarizes current knowledge of substance P and its receptors, as well as its physiological and pathological roles. We focus on recent developments in the immuno-biology of substance P and we discuss the clinical implications of its ability to modulate the immune response